FDA
-
-
-
-
-
-
-
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
-
-
-
-
-
-
-
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
-
-
-
-
-
-
-
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio reports positive phase 3 results for LGMD2I/R9 drug BBP-418
-
335,195 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


